Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study

Current and future treatment strategies in chronic lymphocytic leukemia

(2021) Krish Patel et al.   Journal of Hematology & Oncology

High efficacy of venetoclax plus obinutuzumab in patients with complex karyotype and chronic lymphocytic leukemia

(2020) Othman Al-Sawaf et al.   BLOOD

Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax

(2020) Eugen Tausch et al.   BLOOD

Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial

(2020) Jeff P Sharman et al.   LANCET

Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma

(2020) Travers Ching et al.   BMC CANCER

Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study

(2020) Arnon P. Kater et al.   JOURNAL OF CLINICAL ONCOLOGY

Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial

(2020) Othman Al-Sawaf et al.   LANCET ONCOLOGY

Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia

(2019) Tait D. Shanafelt et al.   NEW ENGLAND JOURNAL OF MEDICINE

Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions

(2019) Kirsten Fischer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Minimal Residual Disease in Chronic Lymphocytic Leukemia: A New Goal?

(2019) Ilaria Del Giudice et al.   Frontiers in Oncology

Minimal Residual Disease in Chronic Lymphocytic Leukemia in the Era of Novel Agents

(2018) Meghan Thompson et al.   JAMA Oncology

Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study

(2018) Arnon P. Kater et al.   JOURNAL OF CLINICAL ONCOLOGY

Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial

(2018) Carol Moreno et al.   LANCET ONCOLOGY

Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL

(2018) Jennifer A. Woyach et al.   NEW ENGLAND JOURNAL OF MEDICINE

Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study Group

(2016) Gabor Kovacs et al.   JOURNAL OF CLINICAL ONCOLOGY

A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study

(2015) A C Rawstron et al.   LEUKEMIA

The Role of Minimal Residual Disease Measurements in the Therapy for CLL

(2013) Sebastian Böttcher et al.   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

Minimal Residual Disease Quantification Is an Independent Predictor of Progression-Free and Overall Survival in Chronic Lymphocytic Leukemia: A Multivariate Analysis From the Randomized GCLLSG CLL8 Trial

(2012) Sebastian Böttcher et al.   JOURNAL OF CLINICAL ONCOLOGY

Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL

(2012) A C Rawstron et al.   LEUKEMIA

Handling Data Below the Limit of Quantification in Mixed Effect Models

(2009) Martin Bergstrand et al.   AAPS Journal

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

(2008) M. Hallek et al.   BLOOD